echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Enantioseparations in Capillary Electrochromatography Using Sulfated Poly -Cyclodextrin-Modified Silica-Based Monolith as Stationary Phase

    Enantioseparations in Capillary Electrochromatography Using Sulfated Poly -Cyclodextrin-Modified Silica-Based Monolith as Stationary Phase

    • Last Update: 2020-12-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As the most popular chiral selectors, β-cyclodextrin (β-CD) and its derivatives have been widely used in enantiomer separations. Among functionalized β-CDs, sulfated β-CDs are recognized as the most effective chiral additives in capillary electrophoresis (CE) separations. Herein, we describe the preparation of a novel sulfated poly β-CD-modified silica-based monolithic column and its use for the enantioseparation of some chiral compounds in the capillary electrochromatography (CEC) mode.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.